CLINICAL TRIALS PROFILE FOR GLUCAGEN

All Clinical Trials for GLUCAGEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00745186 ↗	Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers	Completed	Hospira, Inc.	Phase 1	2007-08-01	The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.
NCT00745186 ↗	Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers	Completed	Hospira, now a wholly owned subsidiary of Pfizer	Phase 1	2007-08-01	The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.
NCT00747968 ↗	The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET	Completed	Aarhus University Hospital	Phase 2/Phase 3	2010-02-01	30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
NCT00747968 ↗	The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET	Completed	Eli Lilly and Company	Phase 2/Phase 3	2010-02-01	30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
NCT00747968 ↗	The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET	Completed	University of Aarhus	Phase 2/Phase 3	2010-02-01	30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
NCT00797823 ↗	Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone	Completed	Juvenile Diabetes Research Foundation	Phase 2	2008-11-01	This study aims to test an insulin and glucagon delivery algorithm designed to be used in conjunction with a continuous glucose monitoring system. This combined glucose sensing/hormone delivery approach is a step on the way to eventual development of an artificial (or automated) pancreas. The insulin and glucagon delivery algorithm is based on the difference between the current blood glucose and the target glucose (proportional error) and the rate of change in blood glucose (derivative error), both adjusted for the recent glucose history. This algorithm is called the Fading Memory Proportional-Derivative (FMPD) Algorithm. The principal investigator of this study has published previous research regarding the use of this algorithm and found it to be well-suited to control blood glucose in type 1 diabetic animals. The addition of glucagon was helpful; better glycemic control with fewer glucose excursions were observed when small intermittent infusions of subcutaneous glucagon were given during times of impending low blood sugar (Ward et al. 2008).
NCT00797823 ↗	Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone	Completed	Oregon Health and Science University	Phase 2	2008-11-01	This study aims to test an insulin and glucagon delivery algorithm designed to be used in conjunction with a continuous glucose monitoring system. This combined glucose sensing/hormone delivery approach is a step on the way to eventual development of an artificial (or automated) pancreas. The insulin and glucagon delivery algorithm is based on the difference between the current blood glucose and the target glucose (proportional error) and the rate of change in blood glucose (derivative error), both adjusted for the recent glucose history. This algorithm is called the Fading Memory Proportional-Derivative (FMPD) Algorithm. The principal investigator of this study has published previous research regarding the use of this algorithm and found it to be well-suited to control blood glucose in type 1 diabetic animals. The addition of glucagon was helpful; better glycemic control with fewer glucose excursions were observed when small intermittent infusions of subcutaneous glucagon were given during times of impending low blood sugar (Ward et al. 2008).

Clinical Trial Conditions for GLUCAGEN

Condition Name

Condition Name for GLUCAGEN
Intervention	Trials
Hypoglycemia	12
Diabetes Mellitus, Type 1	7
Type 1 Diabetes	5
Type 1 Diabetes Mellitus	4

Condition MeSH

Condition MeSH for GLUCAGEN
Intervention	Trials
Diabetes Mellitus	17
Diabetes Mellitus, Type 1	17
Hypoglycemia	15
Diabetes Mellitus, Type 2	4

Clinical Trial Locations for GLUCAGEN

Trials by Country

Trials by Country for GLUCAGEN
Location	Trials
United States	32
Denmark	9
Germany	8
Canada	4
Austria	3

Trials by US State

Trials by US State for GLUCAGEN
Location	Trials
Oregon	5
California	3
New York	3
Minnesota	3
Indiana	3

Clinical Trial Progress for GLUCAGEN

Clinical Trial Phase

Clinical Trial Phase for GLUCAGEN
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	5
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for GLUCAGEN
Clinical Trial Phase	Trials
Completed	22
Recruiting	6
Active, not recruiting	1

Clinical Trial Sponsors for GLUCAGEN

Sponsor Name

Sponsor Name for GLUCAGEN
Sponsor	Trials
Steno Diabetes Center Copenhagen	6
Eli Lilly and Company	5
Zealand Pharma	4

Sponsor Type

Sponsor Type for GLUCAGEN
Sponsor	Trials
Other	37
Industry	23
NIH	2

GLUCAGEN Market Analysis and Financial Projection

Last updated: May 2, 2026

GLUCAGEN (glucagon) Clinical Trials Update, Market Analysis, and 2026-2035 Projection

GLUCAGEN (glucagon for injection; Takeda) is a branded, long-established rescue therapy for severe hypoglycemia. The product’s clinical-trial footprint is narrow and largely maturity-stage: active programs are limited, and the near-term commercial outlook is shaped more by patent/access dynamics, payer behavior, and competition in emergency hypoglycemia rescue than by new-generation clinical differentiation.

---

What is GLUCAGEN and what is its current clinical status?

Product scope

• Brand: GLUCAGEN
• Active ingredient: Glucagon (human recombinant)
• Indication: Treatment of severe hypoglycemia (loss of consciousness or inability to ingest carbohydrates), typically in patients with diabetes.
• Form factors: Injection (historically a kit format with a prefilled component and reconstitution instructions; exact presentation varies by market).

Clinical trials: what the evidence base looks like For rescue glucagon, the bulk of clinical evidence predates the current decade and focuses on:

• Rapid reversal of severe hypoglycemia
• Safety in emergency and peri-emergency administration settings
• Usability endpoints in caregivers and non-professional users

Update posture

• No broad, late-stage pivotal program renewal is evident for GLUCAGEN itself in recent registries at a scale that would typically shift product positioning in the way a new PK/PD or efficacy program would.
• The competitive threat has tended to come from alternative glucagon formulations (including ready-to-use devices and nasal rescue) rather than from GLUCAGEN’s own new clinical differentiation.

Practical implication

• The “clinical update” for GLUCAGEN is mostly incremental: registry maintenance, post-marketing commitments, and labeling refinements in specific jurisdictions rather than novel efficacy drivers.

---

Are there active or recent clinical trials for GLUCAGEN?

A complete and accurate, registry-level trial-by-trial update requires access to an authoritative dataset (e.g., ClinicalTrials.gov, EU CTR) and the ability to enumerate each study tied to “glucagon” while disambiguating GLUCAGEN versus other glucagon products. Without that dataset in-scope here, an authoritative trial list cannot be produced without risking attribution errors.

Result

• This response does not include a trial-by-trial schedule, enrollment, sites, or outcomes for GLUCAGEN because producing that level of specificity without a verified registry extraction would compromise accuracy.

---

What is the competitive landscape for severe hypoglycemia rescue?

GLUCAGEN competes in the “rescue hypoglycemia” category, where differentiation is driven by time-to-treatment, administration simplicity, and payer preference.

Key competitive pressures

1. Ready-to-use glucagon formats
   • Lower user friction in emergencies tends to increase adoption.
   • Device usability influences formulary decisions in some systems.
2. Non-injectable rescue options
   • Nasal glucagon (where available) can change payer and patient behavior, especially where caregiver training is a barrier.
3. Biosimilar or generic availability
   • Glucagon has faced genericization pressure in some markets depending on regulatory status, manufacturing transfers, and exclusivity windows.
4. Hospital and emergency procurement
   • Public tenders and hospital formularies often lag community prescribing but can shift quickly after procurement cycles.

---

Market analysis: GLUCAGEN demand drivers and constraints

Demand drivers

• Incidence of severe hypoglycemia in insulin-treated diabetes (type 1 and type 2 where insulin is used)
• Caregiver and school workplace demand for rescue medication availability
• Diabetes guideline adoption that emphasizes having rescue therapy readily accessible
• Metering and CGM penetration indirectly reduces severe events in some cohorts but does not eliminate the residual need for emergency rescue

Constraints

• Generic/competitive pricing pressure in jurisdictions with accessible alternatives
• Device friction (compared with ready-to-use products) can reduce uptake, even if clinical efficacy is comparable
• Formulary variability by country, insurer, and care setting
• Substitution risk toward nasal or more user-friendly glucagon formats

---

Market sizing and segmentation framework for projections

Because GLUCAGEN is not a monotherapy that drives a new category, the forecast should track category-level demand with assumptions about:

• Units (rescue episodes proxy)
• Net pricing (post-discount blended price)
• Channel mix (hospital vs retail vs institutional)
• Share shifts toward alternative rescue formats

A robust model typically decomposes into:

• Type 1 diabetes: caregiver and school use, insulin dependence
• Type 2 diabetes (insulin users): rescue access for high-risk patients
• Institutional procurement: EMS, hospitals, long-term care

However, precise numeric market size, CAGR, and share without a verified market model source cannot be stated here without creating unsupported figures.

Result

• This response provides a structured projection logic and directional scenarios, not numeric market sizing, to avoid fabricating data.

---

2026-2035 projection: base case and scenario logic

Base case (most likely)

GLUCAGEN revenue growth remains modest and tracks category demand, with:

• Volume stable to low single-digit growth
• Price pressured by competition and contracting cycles
• Share gradually erodes to more user-friendly rescue formats where available

Net effect

• Revenue rises slower than category volume where pricing declines and rebates increase.

Upside scenario

• Faster uptake of GLUCAGEN in specific institutional channels
• Better-managed pricing in certain geographies
• Limited penetration of alternatives due to payer restrictions, tender outcomes, or formulary inertia

Net effect

• Share loss slows and net revenue growth improves.

Downside scenario

• Continued pricing erosion and stronger formulary substitution toward alternative rescue glucagon formats
• Higher generic penetration in additional markets
• Contracting shifts that reclassify GLUCAGEN from preferred to backup option

Net effect

• Declines in net price outpace volume growth.

---

What levers matter most for investors and R&D planners?

1) Patent and exclusivity posture

• The critical investment question is how much of the branded margin can be sustained against generics and competing formulations.
• Once exclusivity erodes, the commercial outcome becomes primarily pricing and channel execution.

2) Formulation and device competition

• If alternative products reduce administration error and training burden, payers and institutions shift faster than clinical evidence alone would predict.

3) Reimbursement and procurement

• Hospital tenders can reallocate large volumes even when retail demand is steady.
• Insurance step edits and prior authorization constraints shape net revenue.

4) Labeling and population coverage

• Broader labeling can support share retention in insulin-treated populations and caregiver settings.

---

Key business implications by stakeholder

For Takeda (brand owner)

• Protect net pricing through contracting strategy and tender discipline.
• Emphasize usability and reliability in emergency contexts.
• Focus on institutional procurement relationships to reduce substitution velocity.

For payer and provider decision-makers

• Rescue hypoglycemia is a safety-driven category.
• Administration simplicity and training burden will often outweigh marginal clinical differences when products are viewed as equivalent for emergency reversal.

For competitors

• Device usability and formulary access are primary battlefields.
• Clinical differentiation alone is rarely enough; reimbursement and workflow fit decide adoption.

For investors

• GLUCAGEN behaves like a maturity-stage branded rescue asset.
• Upside is constrained; downside risk is pricing and substitution speed.

---

Key Takeaways

• GLUCAGEN is a mature rescue therapy for severe hypoglycemia with limited scope for major near-term clinical-trial-driven re-rating.
• Competitive pressure is primarily from alternative glucagon formulations (especially ready-to-use and non-injectable options) and from pricing dynamics tied to payer contracts and generics.
• A 2026-2035 forecast is best modeled around stable-to-slow volume growth and continued net price pressure, with outcomes dominated by formulary and procurement behavior rather than new late-stage efficacy breakthroughs.
• The highest-leverage commercial variables are exclusivity/patent longevity, device usability adoption, and channel-specific reimbursement outcomes.

---

FAQs

1) Is GLUCAGEN expected to launch a new pivotal trial in the near term?
No broad late-stage pivot is evident from the available context; the brand’s clinical contribution is largely maintenance and incremental updates rather than a new efficacy step.

2) What most affects GLUCAGEN demand: hypoglycemia incidence or market access?
Market access and channel pricing typically matter more for net revenue once category demand is stable, especially as alternatives expand.

3) Why do alternative glucagon formulations gain share even with similar clinical goals?
Administration simplicity reduces caregiver training and delays in emergency response, which influences payer and institutional selection.

4) How should projections treat hospital versus retail channels?
Projections should weight channel-specific procurement cycles and rebate structures; substitution often moves faster through institutions than through retail.

5) What is the key downside risk for GLUCAGEN investors?
Faster-than-expected pricing erosion and formulary substitution into ready-to-use or non-injectable rescue glucagon options.

---

References

[1] Takeda. GLUCAGEN (glucagon for injection) prescribing information.